Table 2.
Distribution of multiresistant bacteria by site of infection (patients with evaluable treatment outcome; n = 215)
| Drug-resistance phenotype, % (n) | Patients with documented MRB infection | |||
|---|---|---|---|---|
| Any MRB | VRE | MRSA | ESBL | |
| Total MRB population | 100 % (215) | 19.5 % (42) | 61.4 % (132) | 31.2 % (67) |
| Intraabdominal infection (cIAI) | 32.6 % (70) | 38.6 % (27) | 27.1 % (19) | 50.0 % (35) |
| Skin and soft tissue infection (cSSTI) | 25.6 % (55) | 5.5 % (3) | 90.9 % (50) | 7.3 % (4) |
| Diabetic foot infection (DFI) | 14.0 % (30) | −(0) | 100.0 % (30) | 10.0 % (3) |
| Community-acquired pneumonia (CAP) | 6.0 % (13) | 7.7 % (1) | 84.6 % (11) | 38.5 % (5) |
| Hospital-acquired pneumonia (HAP) | 14.0 % (30) | −(0) | 70.0 % (21) | 30.0 % (9) |
| Blood stream infection (BSI) | 10.2 % (22) | 18.2 % (4) | 68.2 % (15) | 36.4 % (8) |
| Multiple-site infection (MSI) | 12.6 % (27) | 14.8 % (4) | 63.0 % (17) | 44.4 % (12) |
Patients could have more than one MRB